E303 for Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 149 (estimated)
- Sponsor
- Samsung Bioepis Co., Ltd. · Industry
This trial is looking for people with advanced solid tumors. Participants will receive a new treatment called E303 to see how safe and effective it is.
You may be able to join if
- I have advanced solid tumors that have not responded to standard treatment.
- I have been told that I cannot have standard treatment.
- I have refused standard treatment.
- I have tumors that cannot be surgically removed.
You may not be able to join if
- I have spinal cord compression.
- I have active brain metastases.
- I have leptomeningeal disease.
- I have had significant bleeding events.
- I have heart problems.
- I have an active autoimmune disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Loading trial locations…